{
    "clinical_study": {
        "@rank": "112441", 
        "arm_group": {
            "arm_group_label": "RoActemra/Actemra", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This open-label, single arm, multicenter long-term extension study of WA19926 will evaluate\n      the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients with early moderate\n      to severe rheumatoid arthritis who have completed the 104-week WA19926 core study. Eligible\n      patients will receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks for up to 104\n      weeks."
        }, 
        "brief_title": "A Long Term Extension Study of WA19926 of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Patients who complete their last WA19926 core study visit (Week 104) and who may\n             benefit from study drug treatment according to the Investigator's assessment\n\n          -  No current or recent adverse event or laboratory finding preventing the use of the\n             study drug dose of RoActemra/Actemra 8 mg/kg at baseline visit\n\n          -  Women of childbearing potential must agree to use adequate contraception as defined\n             by protocol during the treatment period\n\n        Exclusion Criteria:\n\n          -  Pregnant females\n\n          -  Patients who have withdrawn prematurely from the WA19926 core study for any reason\n\n          -  Treatment with any investigational agent or cell-depleting therapies since the last\n             administration of study drug in WA19926\n\n          -  Treatment with an anti-tumor necrosis factor (TNF) or anti-interleukin (IL) 1 agent,\n             or a T-cell costimulation modulator since the last administration of study drug in\n             WA19926\n\n          -  Immunization with a live/attenuated vaccine since the last administration of study\n             drug in WA19926\n\n          -  Diagnosis since last WA19926 visit (Week 104) of rheumatic autoimmune disease other\n             than rheumatoid arthritis\n\n          -  Diagnosis since last WA19926 visit (Week 104) of inflammatory joint disease other\n             than rheumatoid arthritis\n\n          -  History of severe allergic or anaphylactic reactions to humanized or murine\n             monoclonal antibodies, including tocilizumab and its excipients\n\n          -  Evidence of severe uncontrolled concomitant disease or disorder\n\n          -  Known active or history of recurrent infections\n\n          -  Active tuberculosis requiring treatment in the previous 3 years\n\n          -  History of alcohol, drug or chemical abuse since inclusion in the WA19926 study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01668966", 
            "org_study_id": "ML28080"
        }, 
        "intervention": {
            "arm_group_label": "RoActemra/Actemra", 
            "description": "8 mg/kg iv every 4 weeks, 104 weeks", 
            "intervention_name": "tocilizumab [RoActemra/Actemra]", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Goiania", 
                        "country": "Brazil", 
                        "state": "GO", 
                        "zip": "74110-120"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Juiz de Fora", 
                        "country": "Brazil", 
                        "state": "MG", 
                        "zip": "36010-570"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Curtiba", 
                        "country": "Brazil", 
                        "state": "PR", 
                        "zip": "80030-110"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Porto Alegre", 
                        "country": "Brazil", 
                        "state": "RS", 
                        "zip": "90610-000"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sao Paulo", 
                        "country": "Brazil", 
                        "state": "SP", 
                        "zip": "04266-010"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sao Paulo", 
                        "country": "Brazil", 
                        "state": "SP", 
                        "zip": "04026-000"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicenter, Open-Label, Single Arm, Long Term Extension Study of WA 19926 to Describe Safety During Treatment With Tocilizumab in Patients With Early, Moderate to Severe Rheumatoid Arthritis", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML28080 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Brazil: ANVISA - Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Long-term safety: Incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "approximately 2.5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01668966"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Efficacy according to DAS28-ESR/SDAI/TJC/SJC", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }, 
            {
                "measure": "Sustained drug-free remission according to DAS28-ESR/SDAI remission criteria", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}